EUVIMEDOpdag EUVIMED
FallberichtÜbersichtsarbeit

Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature

Hugo Gonçalves, Duarte Augusto, Paulo Pereira, Carla Ferreira-Campinho, Ana Margarida Correia, Catarina Ferreira, Emanuel Costa, Joana Leite Silva, Ana Roxo Ribeiro, Diogo Esperança Almeida

ARP Rheumatology · 2025-12-30 · 4 (4) · 300-304

DOI: 10.63032/rfpy6607 ↗

At a glance

Fallbericht in ARP Rheumatology, published online on 2025-12-30. Written by Hugo Gonçalves and 9 co-authors. Institution: Rheumatology, Hospital de Braga. Major MEDLINE topics: Myocarditis, Immune Checkpoint Inhibitors, Myositis, Antibodies, Monoclonal, Humanized. Cited 4 times so far (Crossref).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICI) are becoming more frequent with the growing use of these agents in routine clinical oncology. This mechanism enhances the anti-tumor immune response, increasing the risk of activating autoreactive T cells, and leading to immune-mediated manifestations. The spectrum of these manifestations is widely variable. ICI-associated myositis is among the most severe irAEs, being a rare but serious complication with significant morbidity and mortality, particularly when accompanied by myocarditis and/or myasthenic crisis, which can all occur concurrently and worsen clinical outcomes. We report the case of a 78-years-old man with metastatic colon adenocarcinoma who developed ICI-associated myositis with concomitant myocarditis and myasthenic syndrome. In the presented case, the use of tocilizumab, an anti-interleukin 6 (IL-6)-receptor monoclonal antibody, was effective in treating the myositis and myocarditis, but not the myasthenic component of this ICI-associated myositis.

Subjects

MeSH terms (MEDLINE)

MyocarditisImmune Checkpoint InhibitorsMyositisAntibodies, Monoclonal, HumanizedMyasthenia GravisHumansMaleAged

Substances

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanizedtocilizumab

Authors and institutions

  • Rheumatology, Hospital de Braga.
  • Unidade Local de Saúde da Guarda.
  • Unidade Local de Saúde de Braga.
  • Oncology, Hospital de Braga.
  • Hospital de Braga.

Cite

APA

Gonçalves, H., Augusto, D., Pereira, P., Ferreira-Campinho, C., Correia, A. M., Ferreira, C., Costa, E., Silva, J. L., Ribeiro, A. R., & Almeida, D. E. (2025). Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature. ARP Rheumatology, 4(4), 300-304. https://doi.org/10.63032/rfpy6607

Vancouver

Gonçalves H, Augusto D, Pereira P, Ferreira-Campinho C, Correia AM, Ferreira C, et al. Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature. ARP Rheumatology. 2025;4(4):300-304. doi:10.63032/rfpy6607

BibTeX
@article{Gonalves2025,
  author = {Gonçalves, Hugo and Augusto, Duarte and Pereira, Paulo and Ferreira-Campinho, Carla and Correia, Ana Margarida and Ferreira, Catarina and Costa, Emanuel and Silva, Joana Leite and Ribeiro, Ana Roxo and Almeida, Diogo Esperança},
  title = {Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature},
  journal = {ARP Rheumatology},
  year = {2025},
  volume = {4},
  number = {4},
  pages = {300--304},
  doi = {10.63032/rfpy6607}
}
Start for free →